Transient neonatal myasthenia gravis following maternal myasthenia gravis presenting in pregnancy after treatment with Alemtuzumab
Autor: | Ruppa Mohanram Geethanath, Lauren Dhugga, Chike Onwuneme |
---|---|
Rok vydání: | 2020 |
Předmět: | |
Zdroj: | Case Reports in Perinatal Medicine. 9 |
ISSN: | 2192-8959 2192-8932 |
DOI: | 10.1515/crpm-2020-0065 |
Popis: | Ojectives Transient neonatal Myasthenia gravis is a postsynaptic neuromuscular junction disorder seen in 10–21% of infants born to mothers with myasthenia gravis. Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of multiple sclerosis. The possibility of developing Myasthenia gravis in a pregnant mother treated with Alemtuzumab is rare. Case presentation We report a case of transient neonatal myasthenia gravis following treatment with Alemtuzumab for multiple sclerosis in the mother. Conclusions Therapy with Alemtuzumab increases the risk of secondary autoimmune diseases including Myasthenia gravis. |
Databáze: | OpenAIRE |
Externí odkaz: |